Research programme: Parkinson's disease therapeutics - Titan Pharmaceuticals

Drug Profile

Research programme: Parkinson's disease therapeutics - Titan Pharmaceuticals

Alternative Names: Lisuride implant; ProNeura-Lisuride implant; Ropinirole implant - Titan Pharmaceuticals; Ropinirole subdermal implant

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Titan Pharmaceuticals
  • Class Ergolines
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Parkinson's disease
  • Discontinued Dyskinesias

Most Recent Events

  • 09 Aug 2017 US FDA communicates 13 Aug 2017 as review date for the IND application of the ropinirole implant
  • 11 May 2017 Discontinued - Preclinical for Dyskinesia in USA (SC)
  • 10 May 2017 Titan Pharmaceuticals plans a phase I/II pharmacokinetic study of the ropinirole implant in the third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top